BE721003A - - Google Patents
Info
- Publication number
- BE721003A BE721003A BE721003DA BE721003A BE 721003 A BE721003 A BE 721003A BE 721003D A BE721003D A BE 721003DA BE 721003 A BE721003 A BE 721003A
- Authority
- BE
- Belgium
- Prior art keywords
- emi
- solution
- active agent
- animal
- milligrams
- Prior art date
Links
- 239000000243 solution Substances 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 239000013543 active substance Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 6
- 230000003288 anthiarrhythmic effect Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- -1 bis (p-methoxyphenethyl) amino phosphate Chemical compound 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 206010003119 arrhythmia Diseases 0.000 description 3
- 230000006793 arrhythmia Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000036279 refractory period Effects 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000005003 heart tissue Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000005340 bisphosphate group Chemical group 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68264967A | 1967-11-13 | 1967-11-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE721003A true BE721003A (enrdf_load_stackoverflow) | 1969-03-18 |
Family
ID=24740581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE721003D BE721003A (enrdf_load_stackoverflow) | 1967-11-13 | 1968-09-18 |
Country Status (2)
| Country | Link |
|---|---|
| BE (1) | BE721003A (enrdf_load_stackoverflow) |
| NL (1) | NL6813366A (enrdf_load_stackoverflow) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2541113A1 (fr) * | 1982-07-09 | 1984-08-24 | Yason Srl | Application therapeutique de la n-methyl-n-bis (3,4-dimethoxyphenylethyl) amine et de ses sels d'addition avec des acides pharmaceutiquement acceptables |
-
1968
- 1968-09-18 BE BE721003D patent/BE721003A/fr unknown
- 1968-09-18 NL NL6813366A patent/NL6813366A/xx unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2541113A1 (fr) * | 1982-07-09 | 1984-08-24 | Yason Srl | Application therapeutique de la n-methyl-n-bis (3,4-dimethoxyphenylethyl) amine et de ses sels d'addition avec des acides pharmaceutiquement acceptables |
Also Published As
| Publication number | Publication date |
|---|---|
| NL6813366A (enrdf_load_stackoverflow) | 1969-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Endo et al. | Prinzmetal's variant form of angina pectoris. Re-evaluation of mechanisms. | |
| US4496545A (en) | Nonapeptide for treating addictive drug withdrawal conditions | |
| JPH0649651B2 (ja) | 心筋虚血治療用医薬組成物 | |
| Unna | Studies on the toxicity and pharmacology of nicotinic acid | |
| Rosenberg et al. | STUDIES ON DIETHYLAMINOETHANOL: I. Physiological Disposition and Action on Cardiac Arrhythmias | |
| US3560612A (en) | Method of alleviating hypercitricemia | |
| US4568543A (en) | Pharmaceutical composition containing a fibrinolytic agent and a diffusion factor, useful for the treatment of myocardial infarction | |
| BE721003A (enrdf_load_stackoverflow) | ||
| NL8105635A (nl) | Geneesmiddel met transplantaatafstotings- en/of immunologische ontstekingsremmende werking, alsmede werkwijze voor de remming van transplantaatafstoting en/of immunologische ontsteking. | |
| Wilhjelm et al. | The protective action of different barbituric acid derivatives against anoxia in mice | |
| JPS6061527A (ja) | 抗不整脈効力を有する医薬組成物 | |
| Mundy et al. | Pyrazole as an antidote for ethylene glycol poisoning | |
| JPH03501027A (ja) | エネルギー基質 | |
| FR2515961A1 (fr) | Preparations medicamenteuses contenant un derive d'acide tetraiodothyrocarboxylique notamment pour le traitement de l'hypercholesterolemie | |
| HU207455B (en) | Method for producing pharmaceutical preparations suitable for treating postischemical heart-troubles containing captoprile and in given case thrombolitic agent | |
| Stegen et al. | Pharmacologic and toxicologic studies on a new anorexigenic agent—Phendimetrazine | |
| DE2821737C2 (enrdf_load_stackoverflow) | ||
| EP0406327A1 (en) | LONG-TERM COMPOSITION OF PROPAPHENONE AND QUINIDINE FOR THE TREATMENT OF CARDIAC CONDITIONS. | |
| RU2007169C1 (ru) | Средство, обладающее антигипертензивным действием | |
| US4443472A (en) | Method of treating mammals for effects of neuro- and cardiovascular toxins | |
| Scott et al. | The Effect of B-Pyracin and the Lactobacillus casei Factor Upon Hemoglobin Regeneration Following Hemorrhage | |
| Li | TOLERANCE TO THE EFFECTS OF Δ1‐TETRAHYDROCANNABINOL ON THE PRESSOR RESPONSES TO NORADRENALINE IN RATS | |
| US3789124A (en) | Treatment of colitis ulcerosa | |
| DE2828620C2 (de) | Arzneimittel enthaltend Phenylglyoxylsäurederivate | |
| Winsor et al. | Monoamine oxidase inhibitors and angina pectoris |